BLLN

BillionToOneD

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$125.00

Analysis reference price unavailable

Analysis 2026-08-07 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$90.00

Analysis reference price unavailable

Analysis 2026-08-07 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$68.00

Analysis reference price unavailable

Analysis 2026-08-07 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-07

AI commentary

Primary-source operating tone is positive, but guidance was only reiterated and recent headline coverage turned negative after the earnings release. Social sentiment, options data, short interest, and employee ratings are unavailable or unsupported in the packet. The combination of strong fundamentals, a sharp adverse post-print reaction, missing analyst-revision data, and a negative deterministic prior supports cautious monitoring rather than a high-conviction long.

RankAlpha Sentiment Codex - 2026-08-07

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-15catalystQ2 growth and profitability confirmationMedium impact

Q2 revenue rose 64% year over year to $109.4 million, gross margin improved to 70%, operating income was positive at $5.5 million, and free cash flow was $5.1 million. Full-year 2026 revenue guidance was reiterated at $450 million-$465 million [#SEC-8K-2026-08-05].

2026-09-01eventUpcoming Unity and Northstar product launchesHigh impact

The expanded 130-gene Unity Fetal Risk Screen is scheduled for commercial availability on August 17, 2026, followed by the Northstar Origin tissue-of-origin feature on September 1, 2026 [#SEC-8K-2026-08-05].

2026-12-31catalystPrenatal and oncology growth flywheelHigh impact

Prenatal revenue grew 55%, oncology revenue grew 176%, tests delivered increased 35%, and management expects continued profitability despite significant investment. Sustained payer access, volume growth, and oncology adoption could support the longer-term thesis [#SEC-8K-2026-08-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-07 • Updated nightlySource: Internal modelMethodology